-47%

est. 2Y upside i

Series A

FidoCure® is the leader in Precision Medicine for Canine Oncology.

Rank

#385

Sector

Veterinary Oncology & Precision Medicine

Est. Liquidity

~4Y

Data Quality

Data: Medium

FidoCure presents a strong upside opportunity driven by its unique position as a leader in AI-driven precision medicine for canine cancer, backed by the world's largest proprietary dataset and patents.

Last updated: March 10, 2026

Bull (35%)+300%

FidoCure's proprietary AI engine, Fetch™, and its extensive canine cancer dataset drive rapid adoption among veterinary oncologists and general practitioners. Breakthroughs in canine hemangiosarcoma and successful FDA engagement for novel therapies lead to a significant Series C round or strategic acquisition, pushing revenue to $30M+ by 2028 and justifying a $360M+ valuation (4x current estimated valuation) as a leader in precision veterinary oncology with strong human translational medicine potential.

Base (40%)+100%

FidoCure continues to grow steadily, expanding its network of vet clinics and deepening partnerships like Thrive Pet Healthcare. Revenue reaches ~$10M-$15M by 2028, maintaining its market position in canine precision medicine. This growth supports a successful Series B round or a moderate acquisition, valuing the company at approximately $180M (2x current estimated valuation), reflecting solid execution in a growing niche.

Bear (25%)-80%

Despite its strong moat, FidoCure faces slower-than-expected market penetration due to high capital intensity and the long sales cycle in veterinary practices. Larger animal health incumbents begin to offer competitive, albeit less sophisticated, genomic testing services, eroding FidoCure's market share. Revenue growth stalls, leading to a down round or a distressed acquisition at ~$18M, wiping out most common stock value given the $17.1M in liquidation preferences.

Est. time to liquidity~4.0 years

Preference Stack Risk

high

Investors hold $17.1M in liquidation preferences. In an exit at or below the estimated $90M valuation, common stock holders would receive significantly reduced returns, with a near wipeout in a severe downside scenario.

Dilution Risk

high

As a Series A company with high capital intensity, FidoCure will likely require multiple additional funding rounds, leading to further dilution of existing equity holders.

Secondary Liquidity

none

For a Series A company, there is typically no active secondary market for common stock or options.

Questions to Ask at the Interview

Strategic questions based on FidoCure®'s data — designed to show you've done your homework.

  • 1

    “Given the 'medium' incumbent threat, how does FidoCure plan to maintain its competitive edge and prevent larger animal health companies like IDEXX or Zoetis from replicating or acquiring similar AI-driven precision medicine platforms?”

  • 2

    “With current revenue around $3M and a high capital intensity, what are the key milestones and financial targets FidoCure aims to achieve in the next 18-24 months to prepare for its next significant funding round?”

  • 3

    “Considering the Series A stage and the high preference stack, what is the company's strategy for employee liquidity, and are there any plans for secondary sales or tender offers as the company matures?”

Community

Valuation Sentiment

Our model estimates -47% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.